HaleonMEX:HLNN 74 EBITDA Margin % is 25.80% as of Dec. 2025, which is 28% above its 10-year median of 20.12. GuruFocus rates MEX:HLNN with a GF Score™ of 74/100 and a GF Value™ of MXN107.88. The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Haleon ranks better than 79.69% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Haleon's EBITDA for the
six
months ended in Dec. 2025 was MXN34,517 Mil. Haleon's Revenue for the
six
months ended in Dec. 2025 was MXN133,777 Mil. Therefore, Haleon's EBITDA margin for the quarter that ended in Dec. 2025 was 25.80%.
Haleon (MEX:HLNN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Haleon EBITDA Margin % Related Terms
Haleon EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Haleon's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:HLNN vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleon EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haleon's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Haleon's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haleon (MEX:HLNN) has a EBITDA Margin % of 25.80% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Haleon and its competitors. This is 28% above median its historical median of 20.12. Over the past decade, Haleon's EBITDA Margin % has ranged from 13.82 to 25.92. According to the industry distribution chart, Haleon ranks #194 out of 955 companies in the Drug Manufacturers industry, placing it in the top 20.3%.
Is Haleon's EBITDA Margin % too high?
Haleon's current EBITDA Margin % of 25.80% is 28% above median its 10-year median of 20.12. Over the past 10 years, this metric has ranged from a low of 13.82 to a high of 25.92. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Haleon's value of 25.80% is 108.2% above this industry median. Based on the distribution chart, Haleon ranks #194 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Haleon has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Haleon's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Haleon ranks #194 out of 955 companies for EBITDA Margin %. This places Haleon in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. Haleon's value of 25.80% is 108.2% above this benchmark. Historically, Haleon's own EBITDA Margin % has ranged from 13.82 to 25.92 over the past decade. While the company's 10-year median is 20.12 vs. the industry median of 12.39, Haleon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haleon's current EBITDA Margin % of 25.80% is 108.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Haleon and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haleon's current EBITDA Margin % is 25.80%, which is 28% above median its own 10-year median of 20.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleon stock overvalued right now?
Haleon (MEX:HLNN) has a current EBITDA Margin % of 25.80%. The stock's GF Value™ is MXN107.88, compared to a current price of MXN99.17 — trading 8.1% below its estimated fair value. The current EBITDA Margin % is 25.80%, which is 28% above median its 10-year median of 20.12 and 108.2% above the Drug Manufacturers industry median of 12.39. Haleon's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Haleon (MEX:HLNN), the current EBITDA Margin % is 25.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleon (MEX:HLNN) Overvalued in 2026?
Based on GuruFocus' analysis, Haleon stock appears to be undervalued.
The current stock price of MXN99.17 is trading 8.1% below its estimated GF Value™ of MXN107.88.
Key valuation signals for MEX:HLNN:
EBITDA Margin %: 25.80% (28% above median its 10-year median of 20.12)
GF Value™: MXN107.88 vs. price of MXN99.17 (8.1% below fair value)
Industry Position: 108.2% above the Drug Manufacturers median (#194 of 955)
No single metric tells the full story. See the MEX:HLNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
74GF Score
Get the complete analysis for MEX:HLNN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:HLNN has been successfully added to your 
